Results 1 to 2 of 2

Thread: Scotland's cost regulator rejects Vertex CF Drugs

Hybrid View

  1. #1
    Join Date
    Mar 2003

    Scotland's cost regulator rejects Vertex CF Drugs aign=4691e15288-EMAIL_CAMPAIGN_2019_07_25_12_41_COPY_01&utm_medium =email&utm_term=0_a54496134b-4691e15288-431716241

    The Scottish Medicines Consortium’s decision came in its monthly round of drug cost-effectiveness decisions, which included a recommendation to fund Akcea’s pricey rare disease drug Tegsedi (inotersen) for adults with hereditary transthyretin amyloidosis (hATTR).
    Orkambi (lumacaftor+ivacaftor) and Symkevi (tezacaftor+ivacaftor) were deemed too expensive despite an assessment that included greater involvement from patients and clinicians...

  2. #2

Tags for this Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts